Clinical Report: Combining Single-Cell and Spatial Transcriptomics Uncovers Glycolytic Diversity and NEK6-Driven Advancement in Colorectal Cancer

Overview

This study identifies three distinct malignant subtypes in colorectal cancer (CRC), highlighting the Glycolysis-C1 subtype as a key player in tumor progression. The candidate gene NEK6 is associated with high glycolytic activity and poor prognosis, suggesting its potential as a therapeutic target.

Background

Colorectal cancer (CRC) is a leading cause of cancer-related mortality, characterized by significant intratumoral heterogeneity and a complex tumor microenvironment. Understanding the metabolic reprogramming and spatial organization of glycolytic heterogeneity is crucial for developing targeted therapies. The integration of single-cell RNA sequencing and spatial transcriptomics provides insights into the molecular drivers of CRC progression.

Data Highlights

No numerical data available in the provided source material.

Key Findings

• Three distinct malignant subtypes were identified in CRC, with Glycolysis-C1 exhibiting a high-glycolytic state.
• Glycolysis-C1 cells act as a dominant signaling hub, influencing immune cell communication through MIF ligands.
• Pseudotime analysis traced a lineage from low-glycolytic C3 to high-glycolytic C1, indicating dynamic metabolic states.
• NEK6 was identified as a candidate gene linked to CRC risk, with high expression correlating to poor prognosis.
• NEK6 knockdown significantly reduced CRC cell proliferation and glycolysis, impacting macrophage polarization.

Clinical Implications

The identification of NEK6 as a key regulator in high-glycolytic CRC subtypes suggests that targeting this gene may provide a novel therapeutic strategy. Understanding the spatial and molecular landscape of glycolytic diversity can inform treatment approaches and improve patient outcomes.

Conclusion

This research enhances the understanding of glycolytic heterogeneity in CRC and positions NEK6 as a potential therapeutic target, warranting further investigation in clinical settings.

References

1. Frontiers | Integrating Single-cell and Spatial Transcriptomics Reveals Glycolysis Heterogeneity and NEK6-Mediated Progression in Colorectal Cancer
2. Journal of Gastroenterology — The Critical Function of SFRP2 in Enhancing Glycolysis and Disease Advancement in High-Risk Colorectal Cancer Patients Based on a Glycometabolism Prognostic Model
3. npj Digital Medicine — Spatial Multi-Omics Enhanced by Machine Learning Reveals Lactate-Driven Therapeutic Targets and Reprogramming of the Tumor Microenvironment in Cancer
4. Discovery of ASMTL-AS1 and LINC02604 Long Non-Coding RNAs as Potential Diagnostic Biomarkers for Colorectal Cancer
5. ESMO 2026 Guideline: Redefining the Management of Metastatic Colorectal Cancer - OncoDaily
6. Adjuvant Use of Atezolizumab Plus Chemotherapy in DNA Mismatch Repair–Deficient Colon Cancer - The ASCO Post
7. npj Digital Medicine — Multi-dimensional omics integrated machine learning framework identifies macrophage-fibroblast-tumor co-infiltration patterns to predict prognosis in gastric cancer
8. ESMO 2026 Guideline: Redefining the Management of Metastatic Colorectal Cancer - OncoDaily
9. Adjuvant Use of Atezolizumab Plus Chemotherapy in DNA Mismatch Repair–Deficient Colon Cancer - The ASCO Post
10. Frontiers | Integrating Single-cell and Spatial Transcriptomics Reveals Glycolysis Heterogeneity and NEK6-Mediated Progression in Colorectal Cancer